home / stock / alvo / alvo quote
Last: | $12.24 |
---|---|
Change Percent: | 0.08% |
Open: | $12.35 |
Close: | $12.24 |
High: | $12.4 |
Low: | $12.15 |
Volume: | 168,491 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$12.24 | $12.35 | $12.24 | $12.4 | $12.15 | 168,491 | 07-02-2024 |
$12.36 | $12.3 | $12.36 | $12.4 | $12.06 | 230,174 | 07-01-2024 |
$12.16 | $12 | $12.16 | $12.16 | $11.8 | 167,044 | 06-28-2024 |
$12 | $11.93 | $12 | $12.1 | $11.81 | 35,378 | 06-27-2024 |
$12.02 | $12.3 | $12.02 | $12.3 | $11.96 | 72,703 | 06-26-2024 |
$12.77 | $13.3 | $12.77 | $13.3 | $12.685 | 94,194 | 06-25-2024 |
$13.32 | $13.5 | $13.32 | $13.5 | $13.1 | 211,663 | 06-24-2024 |
$13.48 | $13.79 | $13.48 | $13.79 | $13.31 | 123,714 | 06-21-2024 |
$13.51 | $13.5 | $13.51 | $13.65 | $13.27 | 407,158 | 06-20-2024 |
$13.64 | $13.8 | $13.64 | $13.81 | $13.4001 | 154,329 | 06-19-2024 |
$13.64 | $13.8 | $13.64 | $13.81 | $13.4001 | 154,329 | 06-18-2024 |
$13.85 | $14.14 | $13.85 | $14.14 | $13.65 | 442,243 | 06-17-2024 |
$14.05 | $14.32 | $14.05 | $14.32 | $14.035 | 64,520 | 06-14-2024 |
$14.28 | $14.25 | $14.28 | $14.2899 | $14.1 | 84,574 | 06-13-2024 |
$14.23 | $14.65 | $14.23 | $14.65 | $14.16 | 173,741 | 06-12-2024 |
$14.39 | $14.46 | $14.39 | $14.46 | $14.37 | 86,252 | 06-11-2024 |
$14.46 | $13.98 | $14.46 | $14.525 | $13.63 | 218,232 | 06-10-2024 |
$14.04 | $14.07 | $14.04 | $14.14 | $13.965 | 144,393 | 06-07-2024 |
$13.99 | $13.99 | $13.99 | $14 | $13.9438 | 79,725 | 06-06-2024 |
$13.95 | $13.88 | $13.95 | $13.95 | $13.81 | 39,712 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia ® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability of AVT03 to Prolia and Xgeva, respectively, have also met their primary endp...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvote...
REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter a...